Letter to the editor: Neuroleptic malignant syndrome in COVID-19 patients by Soh et al

We read with great interest the recent article by Soh et al. detailing two cases of Neuroleptic Malignant Syndrome (NMS) in COVID-19 patients being treated with favipiravir in Tokyo [1]. We recently published the first case report of NMS in a COVID-19 patient in Los Angeles [2]. Although our patient did not receive favipiravir, he had a history of haloperidol decanoate administration three weeks prior to his presentation. Neurologic symptoms including skeletal muscle injury have been observed in a notable percentage of COVID-19 patients [3].

Source: The American Journal of Emergency Medicine - June 21, 2020 Category: Emergency Medicine Authors: Nitin Ubhayakar, Antonio Liu Source Type: research